China anabolic steroid hormone raw powders professional supplier
Place of Origin: | China |
Brand Name: | RuiiJin |
Certification: | ISO9001 |
Model Number: | 112809-51-5 |
Minimum Order Quantity: | 10g |
---|---|
Price: | Negotiable |
Packaging Details: | Disguised package or according to your requirement |
Delivery Time: | Within 24hours after payment |
Payment Terms: | Western union and moneygram,Bank transfer,Bitcoin, T/T |
Supply Ability: | 3000t/month |
Product name: | Letrozole | Other Name: | Femara |
---|---|---|---|
CAS register number: | 112809-51-5 | Molecular formula: | C17H11N5 |
Molecular weight: | 285.3 | Appearance: | White Powder |
Usage: | Used As API In Treatment Of Breast Disease. | Type: | Anti Estrogen Steroids |
High Light: | 112809-51-5,Letrozole |
Anti-estrogen Series |
|
Tamoxifen Citrate |
CAS No.: 563.64 |
Clomifene Citrate |
CAS No.: 50-41-9 |
Toremifene Citrate |
CAS No.: 89778-27-8 |
Exemestane |
CAS No.: 107868-30-4 |
Anastrozole |
CAS No.: 120511-73-1 |
Letrozole |
CAS No.: 112809-51-5 |
Fulvestrant |
CAS No.: 129453-61-8 |
Letrozole can sometimes also be used:
Product name | Letrozole |
Other name | Femara |
CAS register number | 112809-51-5 |
Molecular formula | C17H11N5 |
Molecular weight | 285.3 |
Molecular structure | ![]() |
Assay | 99% |
Appearance | White Powder |
Minimum order quantity | 10g |
Package: | Exquisite and can according to customers’ requirement |
Shipping leading time | Within 24 hours after receiving the payment |
Payment options | Western Union, MoneyGram, bank transfer, Bitcoin |
For use as first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Letrozoleis also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy: 2.5 mg tablet orally administered once a day without regard to meals.
In patients with advanced disease, Letrozole therapy should continue until tumor progression is evident.
For use as extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy: 2.5 mg tablet orally administered once a day without regard to meals.
The optimal duration of treatment with Letrozole is not known. Treatment should be discontinued if there is a tumor relapse
200ml @ 5 mg/ml
1 gram of Letrozole powder
1 beaker suitable for holding the volume of liquids
19.9 ml of PEG 300
179.1 ml of 190 Proof Grain Alcohol
Letrozole in postmenopausal patients with advanced breast cancer whose Estrogen receptor and / or progesterone receptor positive or receptor status unknown
Letrozole(letrozole) is a type II (non-steroidal) third generation aromatase inhibitor. Clinically it is used to treat postmenopausal women with either estrogen receptor positive or estrogen receptor unknown breast cancer.
Contact Person: Gavin Lee
Tel: +8618806592208